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Introduction
Skeletal muscle differentiation begins in the embryonic somites. 
Soon after their separation from the presomitic mesoderm, so-
mites become partitioned into the dermomyotome and sclero-
tome (Christ and Ordahl, 1995; Stockdale et al., 2000; Pownall 
et al., 2002). Sclerotome cells form the cartilages of the verte-
bral bodies and ribs. The dermomyotome gives rise to the dif-
ferentiated skeletal muscle of the myotome and the connective 
tissues of the dermatome. The dorsomedial region of the dermo-
myotome is the site of early expression of the skeletal muscle–
specifi  c transcription factors MyoD and Myf5 (Sassoon et al. 
1989; Ott et al., 1991; Pownall and Emerson 1992) and is a 
source of cells for the myotome (Christ et al., 1978; Ordahl 
et al., 2000; Kalcheim and Ben-Yair, 2005).
Skeletal muscle differentiation in the somites is promoted 
by members of the Wnt family released from the neural tube 
and overlying ectoderm and by Sonic Hedgehog produced in 
the notochord (Stern et al., 1995; Munsterberg et al., 1995; Fan 
et al., 1997; Borycki et al., 1998, 1999; Tajbakhsh et al., 1998; 
Wagner et al., 2000). Myogenesis is also regulated by Noggin 
and Wnt5b that are synthesized within the segmental plate and 
somites (Pourquie et al., 1996; Hirsinger et al., 1997; Marcelle 
et al., 1997; Reshef et al., 1998; Tonegawa and Takahashi, 1998; 
Amthor et al., 1999; Sela-Donenfi   eld and Kalcheim, 2002; 
Linker et al., 2003). Noggin promotes myogenesis by inhibiting 
bone morphogenetic proteins (BMPs) diffusing from the lateral 
plate mesoderm (Zimmerman et al., 1996; Pourquie et al., 1996; 
Hirsinger et al., 1997; Marcelle et al., 1997; Dietrich et al., 
1998; Reshef et al., 1998; Tonegawa and Takahashi, 1998; 
Amthor et al., 1999).
Although inductive molecules are required for the up-
  regulation of MyoD and Myf5 in the somite and the onset of 
skeletal muscle differentiation (Pownall et al., 2002), both 
  transcription factors are weakly expressed in the presomitic me-
soderm (George-Weinstein et al. 1996; Gerhart et al., 2000; 
Hirsinger et al., 2001; Kiefer and Hauschka, 2001). Cells ex-
pressing MyoD mRNA are also present in the epiblast of the 
chick embryo (George-Weinstein et al., 1996; Gerhart et al., 
2000; Strony et al., 2005). The epiblast gives rise to all tissues 
of the embryo (Fontaine and Le Douarin, 1977; Bellairs, 1986; 
Stern and Canning, 1990) and is a source for embryonic stem 
cell lines (Smith, 2001). When MyoD-positive (MyoD
pos) cells 
are isolated from the epiblast and placed in culture, nearly all 
differentiate into skeletal muscle (Gerhart et al., 2004a). This 
population recruits pluripotent epiblast cells to the skeletal mus-
cle lineage in vitro by releasing an inhibitor of the BMP signal-
ing pathway (Gerhart et al., 2004a). In this study, we examined 
the role that MyoD-expressing epiblast cells play in regulating 
myogenesis in vivo.
Results
Expression of Noggin by MyoD
pos 
epiblast cells
Given that MyoD-expressing epiblast cells produce an inhibi-
tor of the BMP signaling pathway in vitro, and that Noggin is 
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important for muscle differentiation in vivo, we hypothesized 
that MyoD
pos cells would be incorporated into the somites and 
produce Noggin. To test this hypothesis, we examined the sites 
of incorporation of MyoD
pos epiblast cells in the developing 
chick embryo and determined whether they expressed Noggin. 
MyoD
pos cells were tracked in the embryo by tagging them with 
the G8 mAb. G8 recognizes a surface antigen specifi  cally 
  expressed in cells that express MyoD mRNA in the epiblast and 
fetal organs (Gerhart et al., 2001, 2004a; Strony et al., 2005).
Most cells labeled with the G8 mAb in the epiblast (Fig. 1 A) 
were later found in the somites (Fig. 1, C–H). G8-positive 
(G8
pos) cells were concentrated in the dorsomedial and ventro-
lateral regions of the dermomyotome and myotome (Fig. 1, C–F), 
and some expressed sarcomeric myosin, which is a marker for 
differentiation (Fig. 1, G and H).
The majority of cells that had been prelabled with G8 in 
the stage 2 embryo expressed Noggin mRNA and protein in the 
somites, and most cells expressing Noggin mRNA were labeled 
with G8 (Fig. 1, C–F). Labeling for Noggin protein was more 
extensive than the distribution of G8
pos cells (Fig. 1, E and F), 
most likely a refl  ection of diffusion. A few G8
pos/Noggin-
 positive  (Noggin
pos) cells were also found in the mesenchyme of 
the head, neural tube, and eyes (Fig. 2, B, D, and E). The neural 
tube contained cells that expressed Noggin, but not G8 (Fig. 2 B). 
This pattern of Noggin expression is similar to that reported by 
Reshef et al. (1998). Our double-labeling experiments suggest 
that cells that express MyoD mRNA in the epiblast become a 
primary source of Noggin in the somite.
Effects of ablating MyoD
pos cells 
in the epiblast on morphogenesis
To determine if MyoD
pos epiblast cells are critical for skeletal 
myogenesis, they were ablated in the embryo by labeling them 
with the G8 mAb, followed by lysis with complement. Approxi-
mately 70 cells ( 0.4% of the total epiblast cells) were ablated in 
the posterior epiblast of the stage 2 embryo (Fig. 3 A), which is 
where MyoD/G8-expressing cells are located (Fig. 1 A). Embryos 
treated with complement (Fig. 3 B) or G8 alone (not depicted) 
had only a few dead cells throughout the entire epiblast. The spec-
ifi  city of G8/complement treatment was demonstrated by incu-
bating embryos with the E12 mAb and complement. E12 labels a 
subpopulation of epiblast cells that expresses the neurogenic tran-
scription factor NeuroM, but not MyoD (Strony et al., 2005). 
Cells lysed with E12 and complement were located in the central/
anterior and posterior regions of the epiblast (Fig. 3, C and D).
Morphogenesis appeared to progress normally for the fi  rst 
2 d after ablation of MyoD
pos epiblast cells with G8 and comple-
ment (unpublished data). Similar numbers of somites formed 
in treated and control embryos. However, differences were ob-
served as development progressed. Whereas the ventral body 
wall was closed in 5-d control embryos, it remained open in 
G8/complement-treated embryos (Fig. 3, E, H, and I). Embryos 
died between the fi   fth and seventh day after elimination of 
MyoD
pos cells in the epiblast, and all had herniations of the heart 
and abdominal organs through the ventral body wall. Treated 
embryos also exhibited malformations of both eyes, or more 
commonly, the right eye only (Fig. 3, E and H), and twisting 
of the neural tube at the cervical or sacral level (not depicted). 
In some embryos, abnormalities were observed in the facial 
prominences (Fig. 3 E). None of the control embryos had ventral 
body wall, eye, or facial defects (Fig. 3, F and G). The malfor-
mations resulting from ablation of MyoD
pos cells in the epiblast 
are consistent with their locations in older embryos, as deter-
mined by cell-tracking experiments (Fig. 1).
Figure 1.  Expression of Noggin and myosin in MyoD
pos cells originating 
in the epiblast. MyoD
pos cells labeled with the G8 mAb were present in the 
posterior region of the stage 2 epiblast (red cells in A). 4–5 d after labeling 
with G8, stage 25 embryos were examined for expression of Noggin and 
sarcomeric myosin. Regions indicated on the right side of the embryo in the 
hematoxylin and eosin–stained section are shown at higher magniﬁ  cation 
in ﬂ  uorescence photomicrographs of merged images of G8 mAb (labeled 
with Alexa Fluor 488 [green in C and D] and rhodamine [red in E–H]) and 
either Cy3/red-labeled dendrimers to Noggin mRNA (C and D) or Alexa 
Fluor 488/green–labeled antibodies to Noggin (E and F) or myosin 
(G and H). Nuclei were stained with Hoechst dye (blue). Double-labeled 
cells (overlay of red and green) appear yellow (arrows). (C–F) G8
pos/
Noggin
pos cells were observed in the dorsomedial (dm) and ventrolateral 
(vl) dermomyotome and myotome. (G and H) G8
pos/myosin
pos cells were 
present in the myotome. Bar: (A and C–H) 9 μm; (B) 135 μm.MYOD-POSITIVE EPIBLAST CELLS REGULATE MYOGENESIS • GERHART ET AL. 285
Histological analyses of embryos treated with G8 and 
complement revealed that the somites partitioned into the der-
momyotome, myotome, and sclerotome. However, abnormali-
ties were observed in the morphology of the dermomyotome 
and myotome, ranging from an enlargement of the dorsomedial 
and ventrolateral regions (not depicted) to a thickening along 
the entire length (Fig. 3 J) compared with controls (Fig. 3, K 
and L). The boundary between the dermomyotome and myo-
tome in treated embryos was less discrete than that of control 
embryos. These morphological differences were paralleled by 
an increase in cell number in the dermomyotome and myotome-
like structure of G8/complement-treated embryos (Table I). The 
dermatomes of treated embryos were also expanded, whereas 
the sclerotomes of control embryos contained more cells than 
those of treated embryos (Fig. 3 J; Table I). The notochord (Fig. 
3 J) and cartilage rudiments of the limbs (not depicted) appeared 
similar in treated and control embryos. The neural tube was 
properly positioned in ablated embryos (Fig. 3, I and K), except 
for twisting at cranial or sacral levels (not depicted). In contrast, 
the somites of embryos treated with the E12 mAb and comple-
ment were similar to other control embryos, except that the neu-
ral tube was kinked along its length (Fig. 3 L). These experiments 
demonstrate that ablating separate subpopulations of cells in the 
epiblast results in distinctly different malformations.
Effects of ablating MyoD
pos cells 
in the epiblast on myogenesis
The effect of ablating G8
pos/MyoD
pos cells in the epiblast on 
skeletal muscle differentiation was examined by staining for 
  sarcomeric myosin. Whereas control embryos contained an 
abundance of muscle in the dorsomedial and ventrolateral myo-
tomes and limbs, G8/complement-treated embryos had reduced 
myosin staining in the dorsomedial myotome, and severely di-
minished or no detectable myosin in the ventrolateral myotome 
(Fig. 4, D–I; Table II). Differentiated skeletal muscle was also 
decreased in the limbs (Fig. 4, J–L). In all G8/complement-treated 
embryos, differentiation was affected more severely on the right 
side of the embryo than the left (Fig. 4, N and O; Table II).
The effect of ablating G8
pos/MyoD
pos epiblast cells on 
muscle differentiation was accompanied by a decrease in MyoD 
and Myf5 mRNAs in the 5-d embryo (Fig. 5, C–F). At this time, 
few cells in control embryos expressed the marker for myogenic 
precursor cells Pax-3 (Stockdale et al., 2000) in the dermomyo-
tome; however, there was an abundance of Pax3-positive cells 
in the dermomyotome of treated embryos (Fig. 5, I–L). In con-
trast, in the 2.5-d embryo, more Pax-3–positive cells were pres-
ent in the somites of control embryos than those treated with 
G8 and complement (G and H).
Ablation of MyoD
pos epiblast cells also resulted in a de-
creased expression of Noggin in the somites compared with 
control embryos (Fig. 6, C–F). The reduction in Noggin was 
more pronounced on the right side of the embryo than on the 
left (not depicted). In contrast, Noggin expression in the neural 
tube appeared increased in treated embryos compared with 
  controls (Fig. 6, G and H).
Overall, these results complement those of published 
studies. First, an inverse relationship was found between 
  expression of MyoD/Myf5 and Pax-3 in the somite (Goulding 
et al., 1994; Williams and Ordahl, 1994; Marcelle et al., 1995). 
Second, inhibition of MyoD and Myf5 expression in Pax-3-
positive cells occurs in response to BMP signaling (Reshef 
et al., 1998). Third, Pax-3–positive cells are present in Noggin-
null mice (McMahon et al., 1998).
Addition of exogenous Noggin 
to ablated embryos
To test whether exogenous Noggin could compensate for the 
loss of MyoD
pos epiblast cells, Noggin-soaked beads were im-
planted into embryos 2 d after ablating G8
pos/MyoD
pos cells in 
the epiblast. 4 d later, the aforementioned gross malformations 
of the ventral body wall, neural tube, and facial prominences 
were not observed (Fig. 7, A and E). The eyes had normal pig-
mentation after Noggin supplementation, although in some em-
bryos the right eye remained smaller than the left (Fig. 7 A).
The amount of myosin staining in the ventrolateral and 
dorsolateral myotomes of G8/complement-treated embryos 
supplemented with Noggin appeared similar to, or increased, 
compared with that of buffer-treated embryos implanted with 
control beads (Fig. 7, B, C, F, and G). Enhanced myogenesis in 
the myotomes may refl  ect the accumulation of Pax-3– positive 
cells before the addition of Noggin. Exogenous Noggin also 
promoted muscle differentiation in the limbs of ablated   embryos, 
Figure 2.  Expression of Noggin in G8
pos epiblast cells incorporated into the head and neural tube. (A and C) Areas outlined in hematoxylin and eosin–
stained sections are shown at higher magniﬁ  cation in ﬂ  uorescence photomicrographs that are the merged images of Hoechst-stained nuclei, Alexa Fluor 
488–labeled G8 mAb, and Cy3-labeled dendrimers to Noggin mRNA. Double-labeled cells (overlay of red and green) appear yellow. G8
pos cells 
  expressed Noggin mRNA in the neural tube (nt; B, arrows), head mesenchyme (hm; D), and eye (E) of the stage 25 embryo. G8
neg/Noggin
pos cells were 
present in the neural tube (arrowheads). Bar: (A and C) 135 μm; (B, D, and E) 9 μm.JCB • VOLUME 175 • NUMBER 2 • 2006  286
but not to the level of that observed in control embryos (Fig. 7, 
D and H). These results demonstrate that Noggin can, to a sig-
nifi  cant extent, replace the ablated MyoD
pos epiblast cells to 
promote both skeletal myogenesis and normal morphogenesis.
Discussion
The purpose of this study was to determine whether cells that 
express MyoD mRNA in the epiblast play a role in regulating 
skeletal myogenesis in the somites. Initially, these cells were 
found in the posterior epiblast of the two-layered embryo 
  (Gerhart et al., 2000; Strony et al., 2005). A few hours later, 
MyoD
pos cells were present within and lateral to the primitive 
streak (Gerhart et al., 2000; Strony et al., 2005), in a pattern 
similar to that revealed by fate map analyses of prospective par-
axial mesoderm cells (Rosenquist, 1966; Bortier and Vakaet, 
1992; Hatada and Stern, 1994; Nicolas et al., 1996; Jouve et al., 
2002). As expected, most MyoD
pos epiblast cells were incorpo-
rated into the somites.
A few MyoD
pos cells were observed in areas of the epi-
blast fated for nonsomitic tissues, and later, in the sclerotome, 
neural tube, and fetal organs lacking skeletal muscle (Gerhart 
et al., 2000, 2001; Strony et al., 2005). Cells expressing MyoD 
and Myf5 outside of skeletal muscle remain undifferentiated 
(Gerhart et al., 2000, 2001; Tajbakhsh and Buckingham, 1995). 
This raises the possibility that ectopically placed myogenic pre-
cursors, possibly originating in the epiblast, could be a potential 
source of rhabdomyosarcomas. These malignancies are charac-
terized by the expression of myogenic genes and often arise in 
structures lacking skeletal muscle (Dagher and Helman, 1999).
MyoD-expressing cells of the epiblast become a major 
source of Noggin within the somites. Elimination of this popu-
lation in the epiblast resulted in a reduction of Noggin and skeletal 
Figure 3.  Morphological effects of ablating MyoD
pos/G8
pos cells in the epi-
blast. Stage 2 embryos were treated with the G8 or E12 mAb and comple-
ment (G8/cp and E12/cp), or complement (cp) or Hanks’ buffer (bc) only. 
Embryos were incubated in trypan blue to reveal dead cells (blue cells and 
arrows in A–D). Other embryos were grown for 5 (E–G) or 7 d (H; stages 
26 and 30, respectively). Sections were stained with hematoxylin and 
eosin (I–L). The ventral body wall was discontinuous (E, H, and I, arrows) 
and the dermatome (J–L, arrows) and dermomyotome/myotome (dm; J, 
double-headed arrow; K and L, diamond) were thickened in G8/complement-
treated embryos (J) compared with embryos treated with buffer alone 
(K) or E12 and complement (L). G8/complement-treated embryos also ex-
hibited malformations of the eye (F and H, black arrowheads) and facial 
prominences (E, white arrowhead). The notochord (nc) and neural tube (nt) 
appeared normal in G8/complement-treated embryos (J). The neural tube 
was kinked in E12/complement-treated embryos (L). Bar: (A–D and J–L) 
56 μm; (I) 135 μm.
Table I. Number of cells in somite compartments of G8/complement-
treated and control embryos
G8/complement Dermatome Dermomyotome Myotome Sclerotome
right 309 ± 115 192 ± 46 828 ± 370 228 ± 67
left 289 ± 110 178 ± 42 704 ± 221 271 ± 55
Buffer
right 169 ± 34 144 ± 22 246 ± 47 503 ± 61
left 144 ± 26 138 ± 9 246 ± 60 516 ± 107
Embryos were incubated with the G8 mAb and complement or Hanks’ buf-
fer at stage 2 and ﬁ  xed 4.5 d after treatment. The number of nuclei in each 
compartment of the somite was determined by microscopy using the Image-Pro 
Plus image analysis software. Values are the mean ± the SD of 20 and 24 
transverse sections through the wing levels of two treated and two control em-
bryos, respectively. More cells were present in the dermatome, dermomyotome, 
and myotome-like regions of embryos treated with G8 and complement than 
embryos incubated with buffer alone (P ≤ 0.0005). The reverse was found for 
the sclerotome region of the somite (P ≤ 0.0005).
Table II. Number of differentiated skeletal muscle cells in the 
  myotomes of G8/complement-treated and control embryos
G8/complement Number of myosin-positive cells
right (n = 12) 18 ± 13
left (n = 11) 32 ± 5
Buffer
right (n = 16) 95 ± 9
left (n = 17) 94 ± 11
Embryos were incubated with the G8 mAb and complement or Hanks’ buffer at 
stage 2 and ﬁ  xed 4.5 d after treatment. Transverse sections were stained with 
the MF20 mAb to sarcomeric myosin. The number of nuclei in the myotome-like 
structure of two G8/complement-treated embryos and the myotome of two buffer-
treated embryos in sections through the wing level was determined by micros-
copy using the Image-Pro Plus image analysis software. Values are the mean ± 
the SD of the number of sections (n) indicated in parentheses. Fewer myosin-
positive cells were present in G8/complement-treated than control embryos (P ≤ 
0.0005). More myosin-positive cells were present in the myotome-like structure 
on the left side of G8/complement treated embryos than the right (P ≤ 0.005).MYOD-POSITIVE EPIBLAST CELLS REGULATE MYOGENESIS • GERHART ET AL. 287
muscle in the myotomes and limbs in older embryos. These 
  results are consistent with previous studies demonstrating that 
Noggin regulates myogenesis in the somites by inhibiting BMPs 
(Pourquie et al., 1996; Zimmerman et al., 1996; Hirsinger et al., 
1997; Marcelle et al., 1997; Dietrich et al., 1998; Reshef et al., 
1998; Tonegawa and Takahashi, 1998; Amthor et al., 1999; 
Linker et al., 2003). Although some epiblast cells initiated 
the expression of MyoD and the G8 antigen after stage 2 (see 
  Materials and methods), they were unable to completely com-
pensate for those that were ablated earlier in development.
Ventrolateral hypaxial muscles were more severely af-
fected by ablating MyoD
pos epiblast cells than the dorsomedial 
epaxial muscles. This is opposite to what was observed in 
 Noggin-defi  cient mice (McMahon et al., 1998); however, in G8/
complement-treated chick embryos, there was an alternative 
source of Noggin in the neural tube in close proximity to the 
epaxial myotome. The paucity of muscle in the ventral myo-
tome of G8/complement-treated embryos was the most likely 
cause of herniation of organs through the body wall. Malforma-
tions of the eye and facial prominences arising from ablation of 
MyoD
pos epiblast cells may be secondary to a disturbance in the 
differentiation of facial and extraocular muscles, although it is 
possible that Noggin produced by MyoD
pos epiblast cells affects 
nonmyogenic cells.
The malformations that arise as a result of ablation of 
MyoD
pos cells in the epiblast resemble those that are present in 
humans with Axenfeld-Rieger syndrome, an autosomal domi-
nant haploinsuffi   ciency of the Pitx2 gene (Jorgenson et al., 
1978; Semina et al., 1996; Lines et al., 2002). Mutations in 
Pitx2 affect the development of left-sided structures (Logan 
et al., 1998; Piedra et al., 1998; Ryan et al., 1998; St. Amand 
et al., 1998; Yoshioka et al., 1998), whereas elimination of 
MyoD
pos cells in the chick epiblast affected myogenesis, eye 
development, and Noggin expression more severely on the right 
side of the embryo. Although Pitx2 is involved in left– right 
asymmetry, it is expressed symmetrically in myogenic cells of 
the eye, limb, and myotome of the mouse (Campione et al., 
1999; Yoshioka et al., 1998, Kitamura et al., 1999). Pitx2-null 
mice exhibit dysgenesis of the extraocular muscles and thinning 
of the abdominal wall (Kitamura et al., 1999). Given the similarities 
Figure 4.  Effect of ablating MyoD
pos/G8
pos epiblast 
cells on skeletal muscle differentiation in the somites 
and limbs. Stage 2 G8
pos epiblast cells were lysed 
with complement (G8/cp). Controls included embryos 
treated with E12 and complement (E12/cp) or Hanks’ 
buffer only (bc). Embryos were incubated for 4.5–5 d 
(stages 25–26). Regions on the right side of the em-
bryo in hematoxylin and eosin–stained sections (A–C) 
are shown at higher magniﬁ   cation in ﬂ  uorescence 
photomicrographs of merged images of Hoechst-
stained nuclei and rhodamine-labeled antibodies to 
sarcomeric myosin. Less myosin was detected in the 
dorsomedial (dm) and ventrolateral (vl) portions of the 
myotome and limb of G8/complement-treated em-
bryos (D, G, and J) than in those treated with buffer 
(E, H, and K) or E12 mAb/complement (F, I, and L). 
(M) A hematoxylin and eosin–stained section shown 
at higher magniﬁ  cation in N and O. Myosin expres-
sion was affected more severely on the right side of 
the embryo than on the left. Bar: (A–C and M) 135 μm; 
(N and O) 9 μm in D–L.JCB • VOLUME 175 • NUMBER 2 • 2006  288
between the malformations in the chick embryo arising from 
ablation of MyoD
pos epiblast cells and those that result from 
perturbation of Pitx2, it is possible that inhibition of BMP sig-
naling by Noggin is involved in Pitx2 expression in the somite 
during myogenesis. This notion is supported by the fact that 
BMP2 induces, and Noggin inhibits, the expression of Snail/snr 
which represses Pitx2 expression (Isaac et al., 1997; Patel et al., 
1999; Piedra and Ros, 2002; Schlange et al., 2002).
One possible explanation for the asymmetric effects of 
ablating G8/MyoD
pos cells in the stage 2 embryo is that cells 
initiating expression of MyoD in the epiblast after treatment are 
preferentially incorporated into the left side of the embryo. It 
also is possible that MyoD
pos epiblast cells are involved in sig-
naling before their incorporation into the somites. This notion is 
consistent with our fi  nding more MyoD
pos cells on the right side 
of Hensen’s node (Gerhart et al., 2000), which is a structure 
  located at the rostral end of the primitive streak that is a rich 
source of signaling molecules regulating laterality in the em-
bryo (Chapman et al., 2002; Raya and Izpisua Belmonte, 2004). 
The importance of the node in myogenesis was illustrated in the 
mouse inverted viscerus mutant embryo, in which defects in the 
fl  ow of molecules across the node reversed the asymmetric ex-
pression of α-skeletal actin and myosin light chain 3F in the 
myotome (Golding et al., 2004). Cell-tracking experiments that 
follow the pathways of migration of stages 1–3 MyoD
pos epi-
blast cells may shed light on the mechanism whereby muscle 
differentiation is asymmetrically perturbed after their ablation.
Figure 5.  Effect of ablating MyoD
pos/G8
pos epiblast cells on MyoD, Myf5, 
and Pax-3 expression. Stage 2 embryos were treated with the G8 mAb 
and complement (G8/cp) or Hanks’ buffer (bc) and grown for 2 d (stage 
14; G and H) or 4.5 d (stage 25; C–F and I–L). Areas outlined in hematox-
ylin and eosin–stained sections (A and B) are shown at higher magniﬁ  ca-
tion in ﬂ   uorescence photomicrographs that are the merged images of 
Hoechst-stained nuclei and Cy3-labeled dendrimers to MyoD or Myf5 
mRNA, or rhodamine-labeled antibody to Pax-3. Less MyoD and Myf5 mR-
NAs were detected in the somites of G8/complement-treated embryos 
(C and E) than in embryos treated with buffer only (D and F). More Pax-3–
positive cells were present in stage 14 control embryos than treated em-
bryos (G and H), whereas the reverse was found in dorsomedial (dm) and 
ventrolateral (vl) dermomyotomes/myotomes of stage 25 embryos (I–L). 
Bar: (A and B) 135 μm; (C–L) 9 μm.
Figure 6.  Effect of ablating G8
pos/MyoD
pos epiblast cells on Noggin 
  expression. Noggin expression was analyzed 4.5 d after ablating stage 2 
MyoD
pos epiblast cells. Regions indicated in hematoxylin and eosin–stained 
sections (A and B) are shown in ﬂ  uorescence photomicrographs of merged 
images of Hoechst-stained nuclei and Cy3-labeled dendrimers to Noggin 
mRNA (C–H). Less Noggin mRNA was detected in the dorsomedial (dm) 
and ventrolateral (vl) dermomyotome and myotome in G8/complement-
treated embryos (G8/cp) (C and E) than in buffer-treated embryos (bc; D 
and F). (G and H) The reverse was found for Noggin expression in the 
  neural tube (nt). Bar: (A and B) 135 μm; (C–H) 9 μm.MYOD-POSITIVE EPIBLAST CELLS REGULATE MYOGENESIS • GERHART ET AL. 289
We have identifi  ed skeletal muscle stem cells in the epi-
blast based on their expression of MyoD and demonstrated a 
critical role for these cells in regulating myogenesis in vitro and 
in vivo (George-Weinstein et al., 1996; Gerhart et al., 2004a; 
Strony et al., 2005; this study). Choi et al. (1989) postulated that 
the early chick embryo contains founder cells for the myogenic 
lineage based on their observation that skeletal muscle emerges 
in chick blastoderm cultures. In this context, founder cells were 
defi  ned as those that give rise to all cells of a given lineage. In 
contrast, MyoD
pos epiblast cells of the stage 2 embryo do not 
appear to be the sole source of myogenic precursors in the 
  somite. In our cell-tracking experiments, the G8 mAb that had 
been applied in the stage 2 embryo was not detected in most 
cells of the myotome. It is possible that asymmetric divisions 
occurring in the dermomyotome or degradation of the antibody 
may have reduced the signal in myotome cells. However, cells 
expressing Pax-3 did emerge in the dermomyotome after ablat-
ing MyoD
pos cells in the epiblast, and their ability to differenti-
ate was revealed when ablated embryos were supplemented 
with exogenous Noggin. Therefore, under these experimental 
conditions, most Pax-3 precursors do not appear to be the direct 
descendants of MyoD
pos epiblast cells.
Muscle founder/pioneer cells also have been defi  ned in 
the avian embryo as those that are the fi  rst to differentiate and 
enter the myotome (Kahane et al., 1998). In invertebrate 
  embryos, founder/pioneer cells enter the myotome and serve as 
a scaffold for myoblast fusion (Bate, 1990; Baylies and Michelson, 
2001; Dworak and Sink, 2002). Although G8
pos/MyoD
pos 
epiblast cells may be involved in both of these processes, their 
infl  uence clearly extends beyond that of playing a structural role 
in the myotome. Collectively, the data indicate that the primary 
function of MyoD
pos epiblast cells within the somites is to promote 
the differentiation of myogenic precursors by releasing Noggin.
Materials and methods
Tracking MyoD
pos cells from the epiblast into the somites
White Leghorn chick embryos were obtained from BE Eggs and staged ac-
cording to the method of Hamburger and Hamilton (1951). Stage 2 em-
bryos were removed from the shell on the yolk and placed in a tissue 
culture dish. 100 μl of G8 mAb diluted 1:40 in PBS was applied to the 
embryo for 45 min. After rinsing in PBS, embryos were incubated for 
30 min in 100 μl rhodamine-conjugated goat anti–mouse FAb′2 fragments 
(Jackson ImmunoResearch Laboratories) diluted 1:400 and rinsed.   Embryos 
on the yolk were poured into an empty host shell, covered, and incubated 
at 37°C for 2–4 d. Embryos were ﬁ  xed in 4% formaldehyde overnight, 
  embedded in parafﬁ  n, sectioned transversely at 10 μm, and applied to 
gelatin-coated slides. Sections were labeled with an antibody to Noggin 
(R&D Systems) or processed for expression of Noggin mRNA as described 
in the following paragraphs. Sections were mounted in Gelmount (Biomeda) 
and observed with an epiﬂ  uorescence microscope (Eclipse E800; Nikon) 
using 4×/0.2 NA and 60×/1.4 NA oil objectives. Photomicrographs were 
Figure 7.  Effect of exogenous Noggin on 
muscle differentiation in G8/complement-
treated embryos. Noggin-soaked beads were 
implanted lateral to the somites 2 d after ablat-
ing MyoD
pos/G8
pos cells in the stage 2 epi-
blast. Exogenous Noggin prevented body wall 
herniations (arrows in inset of E) and facial de-
fects (arrowhead in A), and promoted normal 
eye pigmentation (arrow in A) and myosin syn-
thesis in the myotome (dm/vl) and limb (F–H). 
The body wall remained incomplete (arrow in I) 
and myosin staining was reduced (J–L) in G8/
complement-treated embryos implanted with 
PBS-soaked beads. Staining for myosin in 
buffer-treated embryos implanted with PBS-
soaked beads is shown in B–D. Bar: (A, E, and I) 
135 μm; (B–D, F–H, and J–L) 9 μm.JCB • VOLUME 175 • NUMBER 2 • 2006  290
produced with the video camera (Evolution QE; Media Cybernetics) and 
Image-Pro Plus image analysis software (Phase 3 Imaging Systems). Tracking 
of G8
pos epiblast cells was conducted in three embryos.
To test for the presence of residual unbound G8 mAb after the 
  initial labeling period, we ﬁ   rst determined the number of G8
pos cells 
  directly after labeling stage 2 embryos. An average of 76 cells in three 
embryos was labeled with G8. When embryos were labeled with G8 
and an Alexa Fluor 488–conjugated secondary antibody, incubated for 
3 h at 37°C, and labeled with a rhodamine-conjugated secondary anti-
body, there was an average of 77 cells labeled with both Alexa Fluor 
488 and rhodamine, and no cells were labeled with either ﬂ  uorochrome 
alone. A third group of embryos was labeled with G8 and Alexa Fluor 
488 secondary antibody, incubated for 3 h, and then exposed to more 
G8 mAb, followed by the rhodamine secondary antibody. In this case, 
there was an average of 80 cells with both Alexa Fluor 488 and rhoda-
mine, and 17 cells were labeled with rhodamine alone. These results 
demonstrate that additional cells are expressing the G8 antigen after the 
initial labeling period; however, there is insufﬁ  cient residual G8 mAb 
present to label those cells. Therefore, unbound G8 mAb does appear to 
be washed out of the embryo during our labeling procedure, thereby 
demonstrating the feasibility of tracking MyoD
pos cells from the stage 
2 epiblast into the mesoderm.
Eliminating MyoD
pos cells in the epiblast
Stage 2 embryos were removed from the shell on the yolk, labeled with the 
G8 mAb, and rinsed as described in the previous section. 100 μl of baby 
rabbit complement (Cedar Lane, Inc.) diluted 1:40 in Hanks’ buffered sa-
line containing 0.1% BSA was applied to the embryo for 30 min at room 
temperature. Control embryos received Hanks’ buffer with BSA, G8 mAb, 
or complement alone. An additional control involved incubating embryos 
in the E12 mAb that labels a subpopulation of cells expressing NeuroM 
mRNA in the epiblast (Strony et al., 2005), followed by the addition of 
complement. The presence of lysed cells was determined directly after 
treatment by incubating embryos in 0.2% trypan blue in PBS for 15 min at 
37°C and counting the number of blue cells. After treatment, embryos not 
exposed to trypan blue were poured into an empty shell and incubated for 
2–7 d. Embryos were analyzed at the gross level and in 10-μm serial sec-
tions after embedding in parafﬁ  n. The number of embryos in each treat-
ment group is listed in Table III. Some sections were stained with hematoxylin 
2 and eosin-Y (Richard Allan Scientiﬁ  c). Other sections were stained with 
antibodies or analyzed for mRNA expression by in situ hybridization, as 
described in In situ hybridization.
Treating embryos with Noggin
MyoD
pos cells of the stage 2 epiblast were lysed with G8 and complement 
and placed in a shell as described in the previous section. Control embryos 
were incubated in Hanks’ buffer only. Embryos were incubated at 37°C to 
reach stages 11–14. Embryos on the yolk were removed from the shell and 
placed in a 100-mm tissue culture dish in preparation for addition of Noggin-
soaked beads.
1 μl Afﬁ  gel blue agarose beads (BioRad) was soaked in either 10 μl 
of a 100-ng human recombinant Noggin (PeproTech) per milliliter of PBS 
solution or PBS alone (Slavkin et al., 2000). A PBS- or Noggin-soaked 
70-μm bead was inserted on the right side of the embryo, lateral to the ﬁ  fth 
and sixth rostral somites, 11th and 12th somites, and between the most 
caudal somite and the rostral end of the presomitic mesoderm. Embryos 
were placed in 60-ml capacity glass bowls, covered, and cultured at 37°C   
for 2–4 d. Embryos were analyzed at the gross level and in transverse, 10-μm 
serial sections. The number of embryos in each treatment group is listed 
in Table III.
In situ hybridization
Parafﬁ   n sections were applied to Teﬂ   on-printed, three-well glass slides   
(Electron Microscopy Sciences) coated with 0.2% gelatin. The in situ hy-
bridization procedure is described in detail in Gerhart et al. (2004b). 
Messenger RNAs for MyoD, Myf5, and Noggin were detected with DNA 
dendrimers conjugated with Cy3 and the following antisense oligonucle-
otide sequences: chicken MyoD, 5′- T  T  C  T  C  A  A  G  A  G  C  A  A  A  T  A  C  T  C  A  C  C  A  T  T-
T  G  G  T  G  A   T  T  C  C  G  T  G  T  A  G  T  A  -3′ (L34006; Dechesne et al., 1994); chicken 
Noggin, 5′-T  C  T  C  G  T  T  A  A  G  A  T  C  C  T  T  C  T  C  C  T  T  G  G  G  G  T  C  A  A  A  -3′ (NM_204123; 
Tonegawa and Takahashi, 1998); and chicken Myf5, 5′-A  T  A  T  A  G  T  G  G  A  T  G-
G  C  A  G  A  G  C  T  G  A  G  G   ATTTCG-3′ (S53719; Neville et al., 1992). Fluores-
cent dendrimers were obtained from Genisphere, Inc. Nuclei were stained 
with Hoechst dye. Double labeling with dendrimers and antibodies 
was performed as previously described (Gerhart et al., 2001, 2004a,b; 
Strony et al., 2005).
Immunoﬂ  uorescence localization
Parafﬁ  n sections were labeled with the MF20 mAb to sarcomeric myosin 
heavy chain (Bader et al., 1982) diluted 1:60, a goat anti–mouse poly-
clonal antiserum to Noggin (R & D Systems) diluted 1:200, or a mAb to 
Pax-3 (Baker et al., 1999) diluted 1:150. Primary antibodies were labeled 
with rhodamine-conjugated goat anti–mouse FAb′2 fragments (Jackson 
  ImmunoResearch Laboratories) or ﬂ  uorescein-conjugated donkey anti–goat 
IgG (CHEMICON International, Inc.), as previously described (George-
Weinstein et al., 1994). The MF20 and Pax-3 mAbs were obtained from 
the Developmental Studies Hybridoma Bank.
Cell counting
The number of nuclei present in the dermatome, dermomyotome, myotome, 
and sclerotome of 20–24 sections through the wing level of two embryos 
treated with the G8 mAb and complement and two embryos incubated 
with Hanks’ buffer was determined in sections stained with Hoechst dye or 
hematoxylin and eosin using the Image-Pro Plus image analysis software. 
The accuracy of cell counting via software analysis was validated by com-
paring cell numbers to those obtained by manually counting cells. The 
number of myosin-positive cells was determined in 11–17 sections from the 
wing level of two treated and two control embryos by manually counting 
MF20-labeled cells via microscopy. Statistically signiﬁ  cant differences in 
populations were determined using the t test.
Table III. Numbers of embryos analyzed by gross inspection and tissue sectioning
Number of Embryos
Gross morphology Histology
2–3 d 4–5 d 7 d 2–2.5 d 4–5 d 7 d
Hanks’ buffer 7 7 2 2 3 1
G8 mAb 1 6 1 1 1
E12 mAb 2
Complement 3 4 1 1
E12 mAb + complement 5 1 2 1
G8 mAb + complement 9 9 5 2 3 1
Hanks’ Buffer Tx + PBS beads 3 2 1 2
G8/complement Tx + PBS beads 5 2 1 2
G8/complement Tx + Noggin beads 4 6 2 3
Embryos were incubated with Hanks’ buffer, antibodies or complement alone, or antibodies and complement at stage 2 and ﬁ  xed for 2–2.5 (stages 14–17), 4–5 
(stages 25–26), or 7 d (stage 30) after treatment. Other embryos were treated at stage 2, grown to stages 11–13, and implanted with beads soaked in PBS or 
Noggin. All embryos were examined morphologically and some embryos were embedded and sectioned (histology). 90% of embryos treated with the G8 mAb and 
complement survived for 5 d.MYOD-POSITIVE EPIBLAST CELLS REGULATE MYOGENESIS • GERHART ET AL. 291
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